Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Thursday

Vanda Pharmaceuticals (NASDAQ:VNDA) is expected to announce its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Vanda Pharmaceuticals to post earnings of ($1.45) per share and revenue of $59.2750 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $7.60 on Thursday. The company has a 50-day simple moving average of $7.09 and a 200-day simple moving average of $5.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.12 and a quick ratio of 3.10. The company has a market cap of $449.16 million, a PE ratio of -5.35 and a beta of 0.62. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VNDA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. Jefferies Financial Group upped their target price on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research note on Wednesday, December 31st. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. B. Riley lifted their price target on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Vanda Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.63.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. boosted its position in shares of Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares during the period. Quarry LP purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at about $53,000. Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals during the 2nd quarter worth approximately $69,000. Boothbay Fund Management LLC purchased a new position in Vanda Pharmaceuticals in the 3rd quarter worth approximately $72,000. Finally, Engineers Gate Manager LP purchased a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $75,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.